Você está na página 1de 28

PRODUCT CATALOG

2010

www.bioporto.com www.antibodyshop.com www.ngal.com

Diagnostics

Welcome to our product catalogue 2010


Thank you for taking the time to review this catalogue of ELISA kits and antibodies. 2009 has been a busy and exciting year here at BioPorto Diagnostics - we added new and innovative products to all areas of our portfolio and we hope you find inspiration in our offering. An area that naturally got special attention is NGAL - our patented biomarker for the early diagnosis of acute kidney injury. We successfully developed The NGAL Test, based on the principle of turbidimetry can be used on a wide range of automated clinical chemistry analyzers. These types of open instruments are already running in laboratories and hospitals all over the world, making this sought after test readily accessible without sizeable investments in expensive new machines. The NGAL Test will be available in the beginning of 2011 and pre-orders are very welcome. The pharma NGAL portfolio is a focus point as well we now offer monoclonal antibodies against NGAL in dog or pig and new ELISA kits for NGAL testing in dog and mouse have been added to the portfolio. We expect to launch ELISA kits for pig and monkey NGAL during 2010. The launch of the unique APC-PCI ELISA kit was an important milestone. Studies indicate that this groundbreaking marker may play a role in selecting sepsis patients for human recombinant APC (Xigris, Eli Lilly) treatment. Also, do not miss out on our focused range of obesity and type-2 diabetes antibodies. It is our endeavour to continue introducing high-quality products that complement the work you do. We strongly believe that product development comes from the customer, not the company, so your feedback and suggestions will be invaluable. Yours sincerely,

Thea Olesen Chief Executive Officer BioPorto Diagnostics A/S

Index

Index
BioPorto Diagnostics
Human NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Animal NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 APC-PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Mannan-binding lectin. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10

Diagnostics

AntibodyShop

Monoclonal antibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cell biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Coagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collectins and related products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Cytokines and hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Marker molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Miscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other blood proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sera and antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Abbreviations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12 12 13 13 14 16 17 18 19 19 20 20 21 21 22 24 25

Alphabetical product index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ordering information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Distributors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

ABOUT US BioPorto Diagnostics A/S is a Danish company which develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Companys developments include a test (NGAL) to diagnose and monitor acute kidney injury. BioPorto was founded in 2000 and is listed on the NASDAQ OMX Copenhagen (symbol: BIOPOR). BioPorto Diagnostics strategy is to develop new methods based on its antibody portfolio that can be patented and achieve a wide use in the diagnosis of various diseases.

QUALITY POLICY BioPorto Diagnostics is committed to the highest level of quality in the manufacture, sale and support of its products. Quality and compliance with all applicable regulatory requirements and customer satisfaction must underlie the companys efforts in manufacturing, marketing, sales, shipping and technical support. BioPorto Diagnostics is committed to effectively implementing and continuously improving its quality management system in accordance with the European IVD directive, the Canadian medical device regulations and ISO 13485 requirements, and is currently seeking certification to this standard. BioPorto Diagnostics aims to please the customers while paying due regard to the interests of the companys stakeholders.

Human NGAL

NGAL
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a small protein expressed in neutrophils and certain epithelia, including the renal tubules. Renal expression of NGAL is dramatically increased after kidney injury, and NGAL is released into both urine and plasma. NGAL levels rise within 2 hours of the insult, making NGAL an early and sensitive biomarker of kidney injury.
Diagnostics

Clinical significance
NGAL levels may also be moderately raised in infections and certain cancers. Rises in NGAL above the baseline level for the patient may indicate acute kidney injury which may lead to acute renal failure. NGAL determination is relevant in, amongst others: Critically ill patients1, 2 Kidney transplants3, 4 Use of i.v. X-ray contrast agents5, 6

30% or more of patients in intensive care may suffer some degree of acute renal failure. The onset of acute renal failure on top of other critical illness increases the mortality dramatically. The prognosis of acute renal failure has not improved significantly over the last four decades. Current diagnostic methods such as serum creatinine or cystatin C measurements only respond after renal function has deteriorated, which may or may not become apparent until one or more days after the original insult. With the NGAL Rapid ELISA Kit, physicians can initiate appropriate management of acute kidney injury within hours rather than days after the insult.

Studies by BioPorto Diagnostics1 have shown that the mean NGAL concentration in urine from healthy donors was 5.3 ng/mL (range 0.7-9.6 ng/mL). The mean NGAL concentration in plasma from healthy donors was 63 ng/mL (range 37-106 ng/mL). NGAL levels rise steeply immediately after kidney injury. In unselected patients admitted to intensive care, the NGAL concentrations in urine ranged from 110 ng/mL to 40,000 ng/mL, while the mean NGAL concentration in EDTA plasma ranged from 25 ng/mL to 3500 ng/mL. Urinary levels above a cut-off of 350 ng/mL or plasma levels above 400 ng/mL are associated with acute renal failure, with a positive predictive value of approximately 90%.

Urinary NGAL after a moderate renal insult


Illustrative time-course of the urinary NGAL level after a moderate renal insult. The red line represents a patient that with 90% positive predictive value will develop acute renal failure, while the green line represents a patient that will not develop acute renal failure.
Urinary NGAL

Diagnostic cut-off

Hours
4
Actin releasing event

Survivor

NGAL ELISA Kits

NGAL ELISA Kit NGAL Rapid ELISA Kit

IVD

In development: The NGAL Test - For your clinical chemistry analyzer


With the NGAL ELISA Kit (KIT 036) and the NGAL Rapid ELISA Kit (KIT 037), urine, plasma or serum samples can be analyzed with conventional ELISA equipment. Automation is also possible on open ELISA workstations. All kit components are ready to use and conveniently stored at 4C.

Diagnostics

KIT 036
4-hour assay format For Research Use Only. Not for use in diagnostic procedures Dynamic range is 100 fold (10 1000 pg/mL)

KIT 037
1-hour rapid assay format For in-vitro diagnostic (IVD) use in selected countries* Dynamic range is 100 fold (0.2 20 ng/mL)

Cat. No. KIT 036 WASH 036-30 WASH 036-250 Cat. No. KIT 037 WASH 037-30 WASH 037-250

Product name NGAL ELISA Kit 25x Wash Solution Concentrate for KIT 036 25x Wash Solution Concentrate for KIT 036 Product name NGAL Rapid ELISA Kit 25x Wash Solution Concentrate for KIT 037 25x Wash Solution Concentrate for KIT 037

Size 96 wells 30 mL 250 mL Size 96 wells 30 mL 250 mL

* Please visit www.bioporto.com for availability in your country. BioPortos NGAL cutoff patent WO2006066587 covering the measurement of NGAL as a marker for acute kidney injury is issued in South Africa, New Zealand and Singapore and is approved for issue in Europe.

References
1. Bangert K, Heslet L, Ghiglione M, Uttenthal LO (2006) NGAL is significantly increased in urine and plasma in acute renal failure. Intensive Care Med 32 (Supplement 1):S10. 2. Makris K, Markou N, Evodia E, Dimopoulou E, Drakopoulos I, Ntetsika K, Rizos D, Baltopoulos G, Haliassos A (2009) Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 47:79-82. 3. Kusaka M, Kuroyanagi Y, Mori T, Nagaoka K, Sasaki H, Maruyama T, Hayakawa K, Shiroki R, Kurahashi H, Hoshinaga K (2008) Serum neutrophil gelatinase-associated lipocalin as a predictor of organ recovery from delayed graft function after kidney transplantation from donors after cardiac death. Cell Transplant 17:129-134. 4. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M (2009) Neutrophil gelatinaseassociated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc 41:158-161. 5. Bachorzewska-Gajewska H, Malyszko J, Sitniewska E, Malyszko JS, Dobrzycki S (2006) Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26:287-292. 6. Di Grande A, Giuffrida C, Carpinteri G, Narbone G, Pirrone G, Di Mauro A, Calandra S, Noto P, Le Moli C, Alongi B, Nigro F (2009) Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur Rev Med Pharmacol Sci 13:197-200.

Animal NGAL

Animal NGAL
NGAL, also called lipocalin 21,2, is the new rapidly responding biomarker of kidney injury whose wide applications include: Drug development (toxicology, dose calculation, drug safety and efficacy assessment) Diagnostic use (kidney injury of any cause) Basic research

Diagnostics

NGAL the biomarker in renal toxicology


Discovery Pre-clinical R&D Clinical P1 Clinical P2 Clinical P3 Clinical P4

Early establishment of drug safety is a continuing challenge in drug development. Exploiting the advantages of new biomarkers related to specific organ damage is attracting the attention of the pharmaceutical industry and regulatory bodies. Clinical studies and experimental animal models have shown that NGAL could be of great value as a marker of kidney damage in both human diagnostics and drug development. Because of its rapid, sensitive and graded response in kidney injury, NGAL permits the early assessment of the renal toxicity or safety of new compounds or treatments.

Important applications of NGAL measurements are: Safety biomarker - NGAL levels rise when the kidney is damaged Efficacy biomarker - NGAL levels fall when kidney damage is treated

Diagnostic use and basic research


NGAL undergoes an early and dramatic up-regulation in various nephron segments after kidney injury, whether this be ischemic3,4, nephrotoxic4,5 or infectious6 in origin. Rises of NGAL concentrations in urine, plasma or serum can be used in research and preclinical studies to detect the extent of kidney injury. The use of NGAL determination will also extend to veterinary diagnostics in farm animals and pets.

Animal NGAL ELISA Kits


3.5 3.0 2.5

OD 450 nm

2.0 1.5 1.0 0.5

Animal NGAL ELISA Kits


BioPorto Diagnostics animal NGAL ELISA kits are based on sandwich ELISA using specific, high-affinity monoclonal antibodies, and the total test time is less than 4 hours.
0.0 100 1000

Key features
Dilution factor

10000

100000

1000000

Highly reproducible results Easy to use Easy storage at 4C

Diagnostics

3.5 3 2.5 2 1.5 . 1 0.5 0


100 200 400 800 1600 3200 6400 12800 25600 51200

20000

NGAL (ng/ml)

15000

10000

5000

0
Serum Urine

Control

Cisplatin

Nephrotoxicity study NGAL concentrations in rat serum and urine from control rats and rats20000 given 10 mg/kg cisplatin intraperitoneally.

15000
Cat. No. KIT 041 KIT 042 KIT 043* KIT 044* KIT 045* *Coming soon. Product name Rat NGAL ELISA Kit Mouse NGAL ELISA Kit Dog NGAL ELISA Kit Pig NGAL ELISA Kit Monkey NGAL ELISA Kit Size 96 wells 96 wells 96 wells 96 wells 96 wells

10000 5000 0

Monoclonal antibodies to animal and human NGAL


To supplement our animal and human NGAL ELISA kits, we also offer a range of monoclonal antibodies to NGAL from the animal species that are most used by researchers and the pharmaceutical industry: mouse | rat | guinea pig | dog | cat | pig | monkey | human This makes NGAL the first kidney injury or toxicology biomarker to cover all the standard animal models of basic research and drug discovery. The antibodies can be used individually or in sandwich pairs and thus have a wide range of applications in immunoassays.

References
1. Kjeldsen L, Cowland JB, Borregaard N (2000) Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta 1482:272-83. 2. Flower DR (1996) The lipocalin protein family: structure and function. Biochem J 318:1-14. 3. Matthaeus T, Schulze-Lohoff E, Ichimura T, Weber M, Andreucci M, Park KM, Alessandrini A, Bonventre JV (2001) Co-upregulation of neutrophil gelatinase-associated lipocalin and matrix metalloproteinase-9 in the postischemic kidney. J Am Soc Nephrol 12:787A. 4. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P (2003) Identification of neutrophil gelatinaseassociated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14:2534-2543. 5. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24:307-315. 6. Ichino M, Kuroyanagi Y, Kusaka M, Mori T, Ishikawa K, Shiroki R, Kurahashi H, Hoshinaga KJ (2009) Increased urinary neutrophil gelatinase associated lipocalin levels in a rat model of upper urinary tract infection. Urol 181:2326-31.

APC-PCI

APC-PCI
Activated protein C-protein C inhibitor (APC-PCI) complex starts being formed as soon as protein C (PC) is activated on the blood vessel wall and the active enzyme (APC) enters into contact with its specific circulating serpin, protein C inhibitor (PCI). The resulting inactive APC-PCI complex is thus a marker of PC activation.

APC-PCI a potential marker for evaluating sepsis patients for APC treatment 60% Sepsis
Sepsis is a devastating condition characterized by systemic activation of the inflammatory and coagulation 40% cascades in response to microbial infection. Apart from antimicrobial therapy, the infusion of human recom binant APC (Xigris , Eli Lilly) is the only treatment documented to reduce the mortality of sepsis patients. 30% The effect of Xigris has been modest1 so far, largely due to the fact that selecting the right patients for this 20% treatment has been a challenge. Now, a study of APC-PCI levels in sepsis patients conducted by BioPorto 10% Diagnostics suggests that measuring APC-PCI levels predicts outcome and may have a role in selecting 2 patients for treatment . 0%
Mortality 50% Non-sepsis

Mortality

Mortality

Mortality

Diagnostics

In the preliminary study both low (APC-PCI levels within the normal range) and high protein C activation Activation of protein C indicated a high mortality in sepsis, whereas a moderate activation (APC-PCI elevated to no more than about 3-fold higher than the upper limit of normal) is associated with a reduced mortality. These data clearly point to the use of APC-PCI for risk stratification of sepsis patients, and also to a possible solution to the problem of how best to select sepsis patients for specific treatments such as Xigris 3.

None

Moderate

High

60% 50% 40% 30% 20% 10% 0% None

Sepsis Non-sepsis

80% 70% 60% 50% 40% 30% 20% 10% 0%

APACHE II<25 APACHE II>25

Moderate

High

None

Moderate

High

Activation of protein C

Activation of protein C

The relationship between mortality and protein C activation differs in critically ill patients with and without sepsis. In sepsis patients, both failure of protein C activation and high protein C activation are associated with high mortality. Sepsis patients without protein C activation and an APACHE II score <25 have a particularly high mortality and may be those who are most likely to benefit from APC treatment2.
80% 70% APACHE II<25 APACHE II>25

60% APC-PCI in coagulation 50%

APC splits blood coagulation factors Va and VIIIa, using protein S and blood coagulation factor V as cofactors. 30% It thereby limits blood coagulation in the vicinity of membrane-bound factors Va and VIIIa. APC may also have 20% an indirect fibrinolytic activity by inhibiting plasminogen activator inhibitor-1 and by limiting the generation of 10% activated thrombin-activatable fibrinolysis inhibitor. APC-PCI levels are elevated in several thrombotic condi0% tions, and measuring APC-PCI levels may be relevant in several conditions such as deep vein thrombosis, None Moderate High myocardial infarctions and aortic aneurysms4-6. Activation of protein C

40%

APC-PCI ELISA Kit

APC-PCI ELISA Kit


BioPorto Diagnostics APC-PCI ELISA Kit measures activated protein Cprotein C inhibitor complex in human plasma. For Research Use Only. Not for use in diagnostic procedures.

Diagnostics

Key features
The only commercially available APC-PCI ELISA Kit Uses exclusive patented antibodies Precoated Microwell strips can be used as strips of 8 or as individual wells All components are stored at 2-8C
Cat. No. KIT 040 Product name APC-PCI ELISA Kit Size 96 wells

References
1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709. 2. Heslet L, Hald R, Recke C, Bangert K, Uttenthal LO (2008) Activated protein C-protein C inhibitor (APC-PCI) complex as a prognostic marker in sepsis. Presented at the The International Sepsis Forum (ISF) 2008, Granada, Spain. 3. Patent application number PCT/DK2007/050194 4. Strandberg K, Astermark J, Bjrgell O, Becker C, Nilsson PE, Stenflo J (2001) Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 86:1400-1408. 5. Bhiladvala P, Strandberg K, Stenflo J, Holm J (2006) Early identification of acute myocardial infarction by activated protein C-protein C inhibitor complex. Thromb Res 118:213-219. 6. Klbel T, Strandberg K, Mattiasson I, Stenflo J, Lindblad B (2006) Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms. J Vasc Surg 43:935-939.

Mannan-binding lectin

Mannan-binding lectin (MBL)


a key test in the assessment of primary immunodeficiency
Mannan-binding lectin (MBL) is an important component of the innate immune system. However, in at least 12% of the average Caucasian population, the circulating level of functional MBL is insufficient. This makes MBL deficiency by far the most common primary immunodeficiency1. While the consequences of MBL deficiency can be quite subtle, several studies have shown that MBL deficiency increases susceptibility to infectious diseases and predisposes to greater severity when infections occur. This correlation has not only led to an increase in the routine diagnostic use of MBL measurement, but has also pointed to a need for therapeutic applications of MBL 2.
Diagnostics

Clinical significance
Deficiency of MBL has been shown to increase the overall susceptibility to infectious diseases and to predispose to greater disease severity; hence especially early and aggressive treatment with antibiotics can be required in risk patients such as those on cancer chemotherapy or immunosuppressant treatment. MBL is a key test parameter in: Patients with a suspected primary immunodeficiency Children with recurrent infections3, 4 Adults with recurrent, severe & persistent infections5, 6 Immunosuppressed patients Cancer chemotherapy7, 8 Transplantation9 Patients with cystic fibrosis10, 11 Patients with autoimmune diseases Systemic lupus erythematosus12 Rheumatoid arthritis13 Women with recurrent spontaneous abortions14, 15

MBL in complement activation


The complement system is a set of blood proteins that form a proteolytic enzyme cascade to help clear pathogens from the body. MBL binds specifically to microbial surface carbohydrates and activates the complement system by means of the MASP-dependent lectin pathway, the MASPs being proteolytic enzyme precursors bound to MBL. This leads to the phagocytosis or lysis of pathogenic microorganisms, including bacteria, viruses, protozoa and fungi. Only the normally oligomerized forms of MBL are functional, i.e. capable of binding efficiently to microbial carbohydrates and associating with the MASPs.

10

MBL Oligomer ELISA Kit

MBL Oligomer ELISA Kit


The MBL Oligomer ELISA Kit employs a monoclonal antibody sandwich which is highly specific for normally oligomerized MBL molecules. Hence the results obtained with the KIT 029 correspond to the circulating levels of functional MBL.

IVD

Diagnostics

Key features
Measures oligomerized functional MBL Measures in plasma and serum All reagents are ready-to-use Storage at 2-8C For in-vitro diagnostic (IVD) use in selected countries* Can be used in many different automated ELISA workstations
Cat. No. KIT 029 WASH 029-30 WASH 029-250 Product name MBL Oligomer ELISA Kit 25x Wash Solution Concentrate KIT 029 25x Wash Solution Concentrate KIT 029 Size 96 wells 30 mL 250 mL

* Please visit www.bioporto.com for availability in your country.

References
1. Turner MW (2003) The role of mannose-binding lectin in health and disease. Mol Immunol 40:423-429. 2. Summerfield JA (2003) Clinical potential of mannose-binding lectin-replacement therapy. Biochem Soc Trans 31:770-773. 3. Koch A, Melbye M, Sorensen P, Homoe P, Madsen HO, Molbak K, Hansen CH, Andersen LH, Hahn GW, Garred P (2001) Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. JAMA 285:1316-1321. 4. Forster-Waldl E, Cokoja L, Foster D, Maurer W (2003) Mannose-binding lectin: comparison of two assays for the quantification of MBL in the serum of pediatric patients. J Immunol Methods 276:143-146. 5. Eisen DP, Dean MM, Boermeester MA, Fidler KJ, Gordon AC, Kronborg G, Kun JF, Lau YL, Payeras A, Valdimarsson H, Brett SJ, Ip WK, Mila J, Peters MJ, Saevarsdottir S, van Till JW, Hinds CJ, McBryde ES (2008) Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis 47:510-516. 6. Garcia-Laorden MI, Sole-Violan J, Rodriguez de Castro F, Aspa J, Briones ML, Garcia-Saavedra A, Rajas O, Blanquer J, CaballeroHidalgo A, Marcos-Ramos JA, Hernandez-Lopez J, Rodriguez-Gallego C (2008) Mannose-binding lectin and mannose-binding lectin-associated serine protease 2 in susceptibility, severity, and outcome of pneumonia in adults. J Allergy Clin Immunol 122:368-374. 7. Peterslund NA, Koch C, Jensenius JC, Thiel S (2001) Association between deficiency of mannose binding lectin and severe infections after chemotherapy. Lancet 358:637-638. 8. Ytting H, Christensen IJ, Jensenius JC, Thiel S, Nielsen HJ (2005) Preoperative mannan-binding lectin pathway and prognosis in colorectal cancer. Cancer Immunol Immunother 54:265-272. 9. Mullighan CG, Heatley SL, Danner S, Dean MM, Doherty K, Hahn U, Bradstock KF, Minchinton R, Schwarer AP, Szer J, Bardy PG (2008) Mannose-binding lectin status is associated with risk of major infection following myeloablative sibling allogeneic hematopoietic stem cell transplantation. Blood 112:2120-2128. 10. Davies JC, Turner MW, Klein N (2004) Impaired pulmonary status in cystic fibrosis adults with two mutated MBL-2 alleles. Eur Respir J 24:798-804. 11. Muhlebach MS, MacDonald SL, Button B, Hubbard JJ, Turner ML, Boucher RC, Kilpatrick DC (2006) Association between mannanbinding lectin and impaired lung function in cystic fibrosis may be age-dependent. Clin Exp Immunol 145:302-307. 12. Garred P, Voss A, Madsen HO, Junker P (2001) Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2:442-450. 13. Saevarsdottir S, Vikingsdottir T, Vikingsson A, Manfredsdottir V, Geirsson AJ, Valdimarsson H (2001) Low mannose binding lectin predicts poor prognosis in patients with early rheumatoid arthritis. A prospective study. J Rheumatol 28:728-734. 14. Jauniaux E, Farquharson RG, Christiansen OB, Exalto N (2006) Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 21:2216-2222. 15. Christiansen OB, Kilpatrick DC, Souter V, Varming K, Thiel S, Jensenius JC (1999) Mannan-binding lectin deficiency is associated with unexplained recurrent miscarriage. Scand J Immunol 49:193-196.

11

Monoclonal antibodies

Monoclonal antibodies
Antibodies are listed according to their antigen by product area and with information about package size, applications, catalog number and conjugation, when applicable. All the antibodies are protein-A or protein-G purified* and the unconjugated antibodies are delivered in a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.5 M sodium chloride and 15 mM sodium azide as preservative. Conjugated antibodies are delivered at a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.14 M NaCl and 15 mM sodium azide.
Cell biology

Perlecan
CSI 001

Thrombospondin I
CSI 002

Tetranectin
HYB 130

Collagen I, III & V


CSI 006 CSI 007 CSI 008

Vitronectin
CSI 003 CSI 004

Fibronectin
CSI 005 HYB 051

Specificity Collagen Type I (human, bovine, pig, sheep, dog, goat) Collagen Type III (human, dog, rat, kangaroo) Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) Fibronectin (bovine) Fibronectin (bovine, human)

Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg

Application EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC, IP EL, WB, IHC, IP EL, WB, IHC, IP EL, WB, IHC, IP EL, WB EL, IHC, IP, AC EL, IHC, IP, AC, WB EL, IHC, IP EL, WB, IHC EL, WB EL, WB EL, IHC, IP EL, IHC EL, WB, IHC, AP EL, WB, IHC EL, WB EL, WB EL, WB

Cat. No. CSI 008-01 CSI 007-01 CSI 006-01 CSI 005-22 CSI 005-32 CSI 005-35 CSI 005-17 HYB 051-05 CSI 001-71 CSI 001-74 CSI 001-76 HYB 130-11 HYB 130-13 HYB 130-14 CSI 002-65 CSI 004-18 CSI 004-27 CSI 003-02 CSI 003-23 CSI 003-21 CSI 003-08

Fibronectin (bovine, human, chicken) Fibronectin (human) Perlecan (bovine)

200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg

Tetranectin (human)

200 g/1 mg 200 g/1 mg 200 g/1 mg

Thrombospondin I (bovine) Vitronectin (bovine, horse, rabbit) Vitronectin (bovine, sheep) Vitronectin (human)

200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg

Vitronectin (human, dog, cat, rabbit, bovine) Vitronectin (human, dog, cat, sheep) *Except HYB 189-01 which is provided as a culture supernatant

200 g/1 mg 200 g/1 mg

12

Monoclonal antibodies

Coagulation Specificity Antithrombin III (human) Pack Size 200 g/1 mg 200 g/1 mg Antithrombin III (human, denatured) Antithrombin III (human, native and denatured) APCAAT complexes, neoepitope (human) Aprotinin 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Aprotinin, biotinylated D-dimer (human, dog) 50 g 200 g/1 mg 200 g/1 mg D-dimer (human, dog), biotinylated Factor IX (human, Christmas factor) 100 g 200 g/1 mg 200 g/1 mg Fibrinogen (human) 200 g/1 mg 200 g/1 mg Hirudin 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Protein C (human) 200 g/1 mg 200 g/1 mg Protein S (human) Thrombin (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg von Willebrand factor (human, vWf) 200 g/1 mg 200 g/1 mg Application EL, WB EL, WB EL, WB EL, IHC EL EL, WB EL EL, WB EL EL EL EL EL, WB EL, WB EL, WB EL, WB EL, WB EL, WB EL EL EL, WB, IHC EL, WB EL EL, WB EL, WB EL EL Cat. No. HYB 230-01 HYB 230-04 HYB 228-12 HYB 228-08 ABS 001-07 ABS 037-18 ABS 037-21 ABS 037-35 ABS 037-18B ABS 015-22 ABS 015-28 ABS 015-22B HYB 133-01 HYB 133-09 HYB 051-04 HYB 051-07 HYB 010-02 HYB 010-03 HYB 010-05 HYB 010-06 HYB 237-01 HYB 237-05 HYB 232-11 HYB 109-03 HYB 109-04 HYB 060-01 HYB 060-02

Collectins and related products Specificity Collectin-43 (bovine, CL-43) Pack Size 200 g/1 mg 200 g/1 mg Conglutinin (bovine) Glycoprotein-340 (human, gp-340) 200 g/1 mg 200 g/1 mg 200 g/1 mg H-Ficolin (human) H-Ficolin (human), biotinylated L-Ficolin (human) 200 g/1mg 100 g 200 g/1 mg 200 g/1 mg M-Ficolin (human) 200 g/1 mg 200 g/1 mg Surfactant protein A (human, hSP-A) Surfactant protein A (human, hSP-A), biotinylated 200 g/1 mg 100 g Application EL, WB EL, WB EL EL, WB, IHC EL, WB, IHC EL EL EL, WB EL, WB EL, IHC EL EL, WB, IHC EL Cat. No. HYB 260-01 HYB 260-04 HYB 263-02 HYB 213-01 HYB 213-06 RIG 334-01 RIG 334-01B ABS 005-16 ABS 005-19 ABS 036-01 ABS 036-05 HYB 238-04 HYB 238-04B

13

Monoclonal antibodies

Collectins and related products (continued) Specificity Surfactant protein D (human, hSP-D) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg Surfactant protein D (human, hSP-D), biotinylated 100 g Application EL, WB, IHC EL, WB, IHC EL, WB EL Cat. No. HYB 245-01 HYB 245-02 HYB 246-04 HYB 246-04B

Complement

MBL

KIT029 HYB131

ClassicalPathway

LectinPathway

AlternativePathway

H-Ficolin
RIG334

M-Ficolin C1-INH
HYB288
C1q C1q MBL/Ficolin B H2O C1s C1r MASP-1 MASP-2 C3 Carbohydrate Carbohydrate C3(H2O) D

ABS036

L-Ficolin
ABS005

C1s

FactorB
HAV005

ABS002

C3(H2O)B

FactorD
GAU010 GAU008

C2

HYB050
C2b

C2

C4

C3(H2O)Bb C3a C4a

Ba Properdin(FactorP)

FactorBa/b
HYB008

C3

HAV004 HYB005
C2a

Properdin
HYB039 3
C4b2a C4b C3bBb

C3d

HAV003 HYB030
C3 C3a C3a

C4

HYB162-04

C3a/C3a(desArg)
GAU013 GAU017
C4b2a3b

C4b
C3bBb3b

HYB162-02

C5 C9

C5-C9 Membraneattackcomplex

HYB029

FactorH
HYB268 GAU018 GAU020

ABS004

Lysisorphagocytosisofthemicroorganism FactorI
HYB061

C5b-9

DIA011

Overviewofthecomplementsystem.ThenameofthecomponentandBioPortoDiagnostics'catalognumberareshownintheblueboxes.

Specificity Complement component C1-inhibitor (human, C1-INH)

Pack Size 200 g/1 mg 200 g/1 mg

Application EL EL EL EL EL, WB EL, WB EL, WB

Cat. No. HYB 288-02 HYB 288-05 ABS 002-09 ABS 002-49 HYB 050-04 HYB 050-05 HYB 050-08

Complement component C1s (human, pro- and activated enzyme)

200 g/1 mg 200 g/1 mg

Complement component C2 (human)

200 g/1 mg 200 g/1 mg 200 g/1 mg

14

Monoclonal antibodies

Complement (continued) Specificity Complement component C3 (human) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg Complement component C3 (human), -chain genetic variant Complement component C3 (rat) Complement component C3a/C3a desArg (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Complement component C3a/C3a desArg (human), biotinylated Complement component C4 (human) 100 g 200 g/1 mg 200 g/1 mg Complement component C5 (human) 200 g/1 mg 200 g/1 mg Complement component C5b-9 (human) Complement component C5b-9 (human), biotinylated Complement component C9 (human) 200 g/1 mg 100 g 200 g/1 mg 200 g/1 mg Complement factor B (caiman) Complement factor B (chicken) Complement factor B (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Complement factor B (human), biotinylated Complement factor D (human) 100 g 200 g/1 mg 200 g/1 mg Complement factor D (human), biotinylated Complement factor H (human, 1H-globulin) 100 g 200 g/1 mg 200 g/1 mg 200 g/1 mg Complement factor H (human, 1H-globulin), biotinylated 100 g 100 g Complement factor I (human) 200 g/1 mg 200 g/1 mg Mannan-binding lectin (chicken, MBL) Mannan-binding lectin (human, horse, pig, MBL) Mannan-binding lectin (human, MBL) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Mannan-binding lectin (human, MBL), biotinylated Mannan-binding lectin (rat, MBL) Properdin (human) 50 g 200 g/1 mg 200 g/1 mg 200 g/1 mg Properdin (human), biotinylated 100 g Application EL, WB EL, WB EL, WB EL, WB EL, IHC EL, WB EL, WB EL EL, WB EL, WB EL, WB EL, WB EL, IHC EL EL, WB EL EL, WB EL, WB EL, WB EL, WB EL, WB EL, WB EL EL, WB EL, WB EL EL, WB EL, WB EL, WB EL EL EL, WB EL, WB EL, WB, IHC EL EL, WB, IHC EL, WB EL, WB EL EL EL, WB EL, WB EL Cat. No. HAV 003-05 HYB 005-01 HYB 030-08 HAV 004-01 HYB 118-02 GAU 013-16 GAU 017-01 GAU 017-01B HYB 162-02 HYB 162-04 HYB 029-02 HYB 029-03 DIA 011-01 DIA 011-01B ABS 004-22 ABS 004-53 KSK 002-01 HYB 022-03 HAV 005-02 HYB 008-02 HYB 008-04 HYB 008-06 HYB 008-06B GAU 008-01 GAU 010-04 GAU 008-01B GAU 018-03 GAU 020-03 HYB 268-01 GAU 020-03B HYB 268-01B HYB 061-01 HYB 061-02 HYB 182-01 HYB 131-14 HYB 131-01 HYB 131-10 HYB 131-11 HYB 131-01B HYB 131-18 HYB 039-04 HYB 039-06 HYB 039-04B

15

Monoclonal antibodies

Cytokines and hormones

Glucagon-like peptide-1 (C-terminal amidated)


ABS033-04 ABS033-10
N-terminus

HYB011-05
N-terminal extension

HYB147-08 HYB147-12 HYB147-13

HYB 011-05
N-terminal extension

ABS 033-04 C-terminus ABS 033-10


N-terminus

HYB147-06 ABS046-03
C-terminus

HY HY HY

1 1 2 7 3 6 7

HYB 011-05
N-terminal extension

ABS 033-04 1 ABS 033-10 1


N-terminus

6 7

HYB 147-08 amide HYB 147-12 HYB 147-13


36 amide 36 amide

36

37

37

ABS 9 033-04 HYB 011-05


N-terminal extension

ABS 033-10
N-terminus

1 6 7

ABS044-491 ABS044-53

HYB 147-08 HYB 147-12 2 HYB 147-13

37

HYB 147-06
C-terminus

GLP-1 Extended form


1 6 7

GLP-1 Active form


7

GLP-1 Metabolite
9 36 (amide)

ABS 033-04 and ABS 033-10 both react with the free N-terminus of GLP-1(7-36)amide or GLP-1(7-37), showing 0.25% or less cross-reactivity with GLP-1(1-36)amide or GLP-1(9-36)amide. ABS 033-10 shows about 50% cross-reactivity with the closely related N-terminus of exendin-4, whereas ABS 033-04 does not cross-react significantly with exendin-4.

ABS 044-49 and ABS 044-53 react with the N-terminus of GLP-1 (GLP-1(9-36)amide and GLP-1(9-37)) and show a low 36 (amide) 7 9 level of cross-reactivity with the active forms of GLP-1 (GLP-1(7-36)amide and GLP-1(7-37)). ABS 046-03 binds GLP-1(1-37), GLP-1(7-37) and GLP-1(9-37). Two different ELISA sandwich setups can be made for measuring non-amidated GLP-1 forms: the first uses ABS 046-03 as a capture antibody with ABS 033-10B as a bioti3 nylated detection antibody cross-reacting about 5% with C-terminally amidated GLP-1. The second combination uses ABS 046-03B as a biotinylated detection antibody and HYB 147-12 as a capture antibody cross-reacting about 16% with 9 36 (amide) C-terminally amidated GLP-1. HYB 147-06 reacts with the amidated C-terminus of GLP-1(7-36)amide and GLP-1(1-36)amide, but not the corresponding unamidated forms. This antibody can be used as capture antibody in sandwich ELISA using biotinylated HYB 147-12 as detection antibody. HYB 147-08, HYB 147-12 and HYB 147-13 all react with different overlapping mid-molecular epitopes found on all forms of GLP-1. HYB 011-05 binds to an epitope on the 1-6 portion of the GLP-1(1-36)amide. It does not react with the two active forms of GLP-1, GLP-1(7-36)amide and GLP-1(7-37).

Specificity -Calcitonin gene-related peptide (-CGRP) Adrenomedulin (human) Chorionic gonadotrophin (human, hCG)

Pack Size 200 g/ 1mg 200 g/ 1mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg

Application EL, IHC EL, IHC EL EL, WB EL, WB EL, WB EL

Cat. No. ABS 026-04 ABS 026-05 ABS 027-01 HYB 093-04 HYB 093-05 HYB 093-09 HYB 057-02

Estradiol-17

200 g/1 mg

16

Monoclonal antibodies

Cytokines and hormones (continued) Specificity Exendin-4 Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Exendin-4, biotinylated 50 g 50 g Gastric inhibitory polypeptide (human, GIP) 200 g/1 mg 200 g/1 mg Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific), biotinylated Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific) Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific), biotinylated Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific) Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) 200 g/1 mg 200 g/1 mg 50 g 200 g/1 mg 200 g/1 mg 50 g 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Glucagon-like peptide-1 (GLP-1, Mid-molecule specific), biotinylated 50 g 50 g Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific) 200 g/1 mg Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific), biotinylated Glucagon-like peptide-2 (human, GLP-2) Leptin 50 g 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Leptin, biotinylated Neuropeptide Y (human, rat, mouse, NPY) Pancreatic polypeptide (human, PP) Peptide histidine-methionine (human, PHM) Peptide YY (human, PYY) Tumor necrosis factor (human, TNF-) Vasoactive intestinal peptide (human, bovine, porcine, rat, VIP) 100 g 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Application EL EL EL EL EL EL EL, IHC EL EL EL, IHC EL EL EL EL EL EL EL, WB EL, WB, IHC EL, WB EL EL EL EL EL EL, IHC EL EL EL EL, IHC EL EL EL, IHC EL EL EL Cat. No. ABS 012-20 ABS 012-23 ABS 012-24 ABS 012-35 ABS 012-23B ABS 012-35B ABS 021-04 ABS 021-05 HYB 011-05 HYB 147-06 HYB 147-06B ABS 033-04 ABS 033-10 ABS 033-10B ABS 044-49 ABS 044-53 HYB 147-08 HYB 147-12 HYB 147-13 HYB 147-08B HYB 147-12B ABS 046-03 ABS 046-03B HYB 006-02 ABS 022-03 ABS 022-06 ABS 022-11 ABS 022-11B ABS 028-08 ABS 030-06 ABS 020-03 ABS 029-01 HYB 141-08 HYB 141-09 ABS 023-02

Enzymes Specificity Alkaline phosphatase (AP) Trypsin (human) Trypsin (human), biotinylated Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 100 g Application EL EL, WB EL, WB EL Cat. No. HYB 252-08 HYB 021-03 HYB 021-08 HYB 021-03B

17

Monoclonal antibodies

Marker molecules Specificity -Fetoprotein (human, AFP) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Acetylcholinesterase (bovine brain, AChE) Acetylcholinesterase (human brain, AChE) Acetylcholinesterase (human brain, bovine brain, AChE) Amyloid- peptide (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Butyrylcholinesterase (human, BtChE) Neutrophil gelatinase-associated lipocalin (dog, NGAL) 200 g/1 mg 200 g/1 mg 200 g/1 mg Neutrophil gelatinase-associated lipocalin (dog, NGAL), biotinylated Neutrophil gelatinase-associated lipocalin (human, NGAL) 50 g 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Neutrophil gelatinase-associated lipocalin (human, NGAL), biotinylated 50 g 50 g Neutrophil gelatinase-associated lipocalin (monkey, NGAL) Neutrophil gelatinase-associated lipocalin (mouse, NGAL) 200 g/1 mg 200 g/1 mg 200 g/1 mg Neutrophil gelatinase-associated lipocalin (mouse, NGAL), biotinylated Neutrophil gelatinase-associated lipocalin (pig, NGAL) 50 g 200 g/1 mg 200 g/1 mg Neutrophil gelatinase-associated lipocalin (pig, NGAL), biotinylated Neutrophil gelatinase-associated lipocalin (rat, NGAL) 50 g 200 g/1 mg 200 g/1 mg Neutrophil gelatinase-associated lipocalin (rat, NGAL), biotinylated Placental protein 14 (human, PP14, glycodelin A) 50 g 200 g/1 mg 200 g/1 mg 200 g/1 mg Pregnancy-associated plasma protein A (human, PAPP-A) 200 g/1 mg 200 g/1 mg 200 g/1 mg Procollagen type I C-terminal propeptide (human, PICP) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Procollagen type IIA N-terminal propeptide (human, PIIANP) 200 g/1 mg Application EL EL EL EL EL EL, WB EL, WB EL, WB EL EL EL EL, AP EL EL, WB EL, WB EL EL, WB EL, WB EL, WB EL, WB EL, WB, IHC EL, WB, IHC EL, WB EL EL EL EL, WB EL, WB EL EL, WB EL EL EL, IHC EL, WB EL EL, IHC EL, IHC EL, IHC EL, IHC EL EL, IHC EL EL EL EL EL, IHC Cat. No. HYB 097-04 HYB 097-06 HYB 097-07 HYB 097-08 HYB 097-09 HYB 101-03 HYB 111-05 HYB 190-01 HYB 310-03 HYB 310-04 HYB 310-07 HYB 310-08 HAH 002-01 ABS 047-14 ABS 047-17 ABS 047-14B ABS 038-04 ABS 038-14 ABS 038-15 ABS 038-26 HYB 211-01 HYB 211-02 HYB 211-05 HYB 211-01B HYB 211-02B ABS 038-23 ABS 043-10 ABS 043-29 ABS 043-29B ABS 048-17 ABS 048-28 ABS 048-28B ABS 039-08 ABS 039-32 ABS 039-32B BTE 001-13 BTE 001-16 BTE 001-18 ABS 006-01 ABS 006-24 BTE 004-09 BTE 002-04 BTE 002-08 BTE 002-18 BTE 002-32 BTE 003-02

18

Monoclonal antibodies

Microbiology Specificity Clostridium botulinum E toxoid (Botulin E toxoid) Pack Size 200 g/1 mg 200 g/1 mg Clostridium tetani toxoid (Tetanus toxoid) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Corynebacterium diphtheriae toxoid (Diphtheria toxoid) 200 g/1 mg 200 g/1 mg Influenza A virus 200 g/1 mg 200 g/1 mg Influenza A virus, biotinylated 100 g 100 g Influenza B virus 200 g/1 mg 200 g/1 mg 200 g/1 mg Influenza B virus, biotinylated Mycobacterium tuberculosis, Ag85 Mycobacterium tuberculosis, ESAT-6 Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) Nitrobacter hamburgensis nitrite oxidoreductase 100 g 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Pneumolysin Poliovirus type 1 200 g/1 mg 200 g/1 mg 200 g/1 mg Poliovirus type 2 200 g/1 mg 200 g/1 mg Poliovirus type 3 200 g/1 mg 200 g/1 mg Streptolysin 200 g/1 mg Application EL EL EL EL EL EL EL EL EL, WB EL, WB EL, WB EL EL EL EL, WB EL, WB EL EL, WB EL, WB EL, WB EL, WB, IHC EL, WB, IHC EL, WB EL EL EL EL EL EL EL Cat. No. HAV 001-02 HAV 001-06 HYB 278-01 HYB 278-10 HYB 278-14 HYB 278-15 HYB 278-17 HYB 123-05 HYB 123-09 HYB 156-01 HYB 156-02 HYB 156-01B HYB 156-02B HYB 116-01 HYB 116-02 HYB 116-03 HYB 116-03B HYT 27 HYB 076-08 HBT 10 HYB 153-01 HYB 153-02 HYB 041-01 HYB 295-15 HYB 295-17 HYB 294-02 HYB 294-06 HYB 300-05 HYB 300-06 HAB 003

Miscellaneous Specificity Amodiaquine Atrazine Biotin Chloroquine Gliadin peptide Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Immunoglobulin heavy chain (chicken, IgY) Immunoglobulin light chain (rat, chain) MHC class I chain (chicken) MHC class II chain (chicken) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Application EL EL EL, WB EL EL EL EL, WB EL, AC WB WB, IHC, AP, FC Cat. No. HYB 320-04 HYB 225-01 HYB 212-01 HYB 317-01 HYB 314-01 HYB 314-02 HYB 208-03 MARK 1 KSK 001-03 KSK 001-02

19

Monoclonal antibodies

Miscellaneous (continued) Specificity Ovalbumin (chicken) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Ovalbumin (chicken, denatured) 200 g/1 mg 200 g/1 mg 200 g/1 mg Thioguanine (2-amino-6-mercaptopurine) 200 g/1 mg 200 g/1 mg 200 g/1 mg Application EL, IP EL, IP EL EL EL, WB EL, WB EL, WB EL EL EL Cat. No. HYB 099-01 HYB 099-02 HYB 099-09 HYB 099-11 HYB 094-05 HYB 094-06 HYB 094-07 HYB 125-03 HYB 138-02 HYB 144-04

Oncology Specificity Plasminogen activator inhibitor type I (human, PAI-1) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Tissue plasminogen activator (human, tPA) Urokinase plasminogen activator (human, uPA) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Urokinase plasminogen activator receptor (human, uPAR) 200 g/1 mg 200 g/1 mg 200 g/1 mg Application EL, WB, IHC, AP EL, WB, IHC, AP EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC EL, WB, IHC, FC EL, WB EL, WB, IHC, FC EL, WB, IHC Cat. No. MON I-1 MON I-2 MON I-3 MON I-5 MON I-6 MON T-1 MON U-5 MON U-6 MON U-12 MON U-16 MON R-3 MON R-4 MON R-5

Other blood proteins Specificity 1-Antitrypsin (human, 1-AT) 1-Antitrypsin (human, 1-AT, native and denatured) Albumin, bovine serum (BSA) Albumin, bovine serum (BSA, denatured) Albumin, human serum (HSA) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Albumin, human serum (HSA, denatured) 200 g 200 g/1 mg Apolipoprotein A-1 (human) Apolipoprotein B (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg 2-Microglobulin (caiman) 2-Microglobulin (human) 200 g/1 mg 200 g/1 mg Application EL, WB EL, WB EL, WB EL EL, WB EL, WB EL, WB EL, WB EL, WB EL, WB EL, WB EL EL WB EL, AP Cat. No. HYB 185-02 HYB 191-01 HYB 267-01 HYB 261-02 HYB 192-01 HYB 192-02 HYB 193-05 HYB 189-01* HYB 189-09 HYB 069-01 HYB 069-02 HYB 069-03 HYB 069-04 KSK 003-01 HYB 290-03

20

* Only available as a culture supernanant

Monoclonal antibodies

Other blood proteins (continued) Specificity Gc-globulin (human) Pack Size 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Gc-globulin (human), biotinylated 50 g 50 g Gelsolin (human) Haptoglobin (human) Hemopexin (human) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Hemopexin (human), biotinylated 100 g 100 g MDA treated low-density lipoprotein (human, LDL) 200 g/1 mg 200 g/1 mg 200 g/1 mg 200 g/1 mg Application EL, WB EL, WB EL EL EL EL EL, WB EL EL, WB EL EL, WB EL EL, WB EL, WB EL, WB EL, WB Cat. No. HYB 249-01 HYB 249-02 HYB 249-05 HYB 249-10 HYB 249-01B HYB 249-02B ABS 017-20 HYB 170-06 ABS 013-04 ABS 013-32 ABS 013-04B ABS 013-32B HYB 262-01 HYB 262-03 HYB 262-04 HYB 262-05

Sera and antigens Specificity EcoR1 (IgG/k control antibody) Human IgE (non-immune), without azide Human IgE (non-immune), with azide Human IgE (non-immune), biotinylated MBL standard serum (human) - 1000 (AU) MBL oligomer deficient serum, B/B genotype (human) Pack Size 1 mg 100 g/1 mg 100 g/1 mg 100 g 1 mL 1 mL Cat. No. HYB 098-08 DIA HE1 DIA HE1A DIA HE1B SER 101 SER 102

SDS-PAGE (16%). Lane 1: Shows molecular weight markers. Lane 2: DIA HE1 purified human IgE, 185 kDa. Lane 3: IgE, purified from serum from a myeloma patient.

Human IgE (non-immune) DIA HE1

The DIA HE1 IgE preparation is an affinity-purified, fully human IgE antibody with kappa light chains. The IgE is produced in vitro from a monoclonal hybridoma. This unique source guarantees freedom from contamination by other immunoglobulin isotypes. Due to its very low batch-to-batch variation, this antibody is suitable as a standard in quantitative IgE assays, used in the field of allergy treatment and diagnostics. Other applications include research in immunochemistry and cellular immunology.

Abbreviations
AC AP EL FC Affinity chromatography Affinity purification Enzyme-linked immunosorbent assay (ELISA) Flow cytometry IHC IP WB Immunohistochemistry Immunoprecipitation Western blotting

21

Alphabetical index

Alphabetical product index


ELISA kits and monoclonal antibodies listed by specificity
-Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 1-Antitrypsin (human, 1-AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 1-Antitrypsin (human, 1-AT, native and denatured) . . . . . . . . 20 -Calcitonin gene-related peptide (-CGRP) . . . . . . . . . . . . . . . 16 Acetylcholinesterase (bovine brain, AChE) . . . . . . . . . . . . . . . . . . 18 Acetylcholinesterase (human brain, AChE) . . . . . . . . . . . . . . . . . . 18 Acetylcholinesterase (human brain, bovine brain, AChE) . . . . . 18 Activated protein C-protein C inhibitor (APC-PCI) . . . . . . . . . . . . 8 Activated protein C-1-antitrypsin, neoepitope (human) . . . . . 13 Adrenomedulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Albumin, bovine serum (BSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Albumin, bovine serum (BSA, denatured) . . . . . . . . . . . . . . . . . . 20 Albumin, human serum (HSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Albumin, human serum (HSA, denaturated) . . . . . . . . . . . . . . . . 20 Alkaline phosphatase (AP). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 2-amino-6-mercaptopurine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Amodiaquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Amyloid- peptide (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Antithrombin III (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Antithrombin III (human, denatured) . . . . . . . . . . . . . . . . . . . . . . . . 13 Antithrombin III (human, native and denatured) . . . . . . . . . . . . . . 13 APC-AAT complexes, neoepitope (human). . . . . . . . . . . . . . . . . . 13 APC-PCI. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Apolipoprotein A-1 (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Apolipoprotein B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Aprotinin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Atrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Complement component C3 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . Complement component C3a/C3a desArg (human) . . . . . . . . . Complement component C4 (human) . . . . . . . . . . . . . . . . . . . . . . Complement component C5 (human) . . . . . . . . . . . . . . . . . . . . . . Complement component C5b-9 (human) . . . . . . . . . . . . . . . . . . . Complement component C9 (human) . . . . . . . . . . . . . . . . . . . . . . Complement factor B (caiman). . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement factor B (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement factor B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement factor D (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement factor H (human, 1H-globulin) . . . . . . . . . . . . . . . . Complement factor I (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Conglutinin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Corynebacterium diphtheriae toxoid (Diphtheria toxoid) . . . . .

15 15 15 15 15 15 15 15 15 15 15 15 13 19

Diagnostics

D
D-dimer (human, dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 DBP (human, Vitamin-D binding protein) . . . . . . . . . . . . . . . . . . . . 21 Diphtheria toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Dog NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

E
EcoR1 (IgG/k control antibody) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Estradiol-17 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Exendin-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17

F
Factor IX (human, Christmas factor) . . . . . . . . . . . . . . . . . . . . . . . . Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fibrinogen (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fibronectin (bovine). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fibronectin (bovine, human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fibronectin (bovine, human, chicken) . . . . . . . . . . . . . . . . . . . . . . . Fibronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ficolin-H (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ficolin-L (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ficolin-M (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 18 13 12 12 12 12 13 13 13

1H-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 2-Microglobulin (caiman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 2-Microglobulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Biotin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Botulin E toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 BSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 BSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Butyrylcholinesterase (human, BtChE) . . . . . . . . . . . . . . . . . . . . . 18

C
Calcitonin-gene related peptide (human, CGRP) . . . . . . . . . . . . Chloroquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chorionic gonadotrophin (human, hCG) . . . . . . . . . . . . . . . . . . . . Christmas factor (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Clostridium botulinum E toxoid (Botulin E toxoid) . . . . . . . . . . . Clostridium tetani toxoid (Tetanus toxoid) . . . . . . . . . . . . . . . . . . Coagulation factor IX (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collagen Type I (human, bovine, pig, sheep, dog, goat) . . . . . . Collagen Type III (human, dog, rat, kangaroo) . . . . . . . . . . . . . . Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Collectin-43 (bovine, CL-43) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Complement component C1-inhibitor (human, C1-INH) . . . . . Complement component C1s (human, pro- and activated enzyme) . . . . . . . . . . . . . . . . . . . . . . . Complement component C2 (human) . . . . . . . . . . . . . . . . . . . . . . Complement component C3 (human) . . . . . . . . . . . . . . . . . . . . . . Complement component C3 (human), -chain genetic variant . 16 19 16 13 19 19 13 12 12 12 13 14 14 14 15 15

G
Gastric inhibitory polypeptide (human, GIP) . . . . . . . . . . . . . . . . . 17 Gc-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Gelsolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Gliadin peptide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) . . . . . . . 16, 17 Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) . . . . . . . . . . . . . . . . . 16, 17 Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific) . 16, 17 Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific) . . . . . . . . . . . . . . . . . . 16, 17 Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) . . 16, 17 Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific). . . . . . . . . . . . . . . . . . . . . . . . . . 16, 17 Glucagon-like peptide-2 (human, GLP-2) . . . . . . . . . . . . . . . . 16, 17 Glycodelin A (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Glycoprotein-340 (human, gp-340) . . . . . . . . . . . . . . . . . . . . . . . . . 13

22

Alphabetical index

H
Haptoglobin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Hemopexin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 hCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 H-Ficolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 HNL (human neutrophil lipocalin) . . . . . . . . . . . . . . . . . . . . . . 4, 7, 18 HSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 HSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 hSP-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 hSP-D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Human IgE (non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

O
Ovalbumin (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Ovalbumin (chicken, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Diagnostics

P
PAI-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 Pancreatic polypeptide (human, PP) . . . . . . . . . . . . . . . . . . . . . . . 17 Peptide histidine-methionine (human, PHM) . . . . . . . . . . . . . . . . 17 Peptide YY (human, PYY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Perlecan (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Pig NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Placental protein 14 (human, PP14, glycodelin A) . . . . . . . . . . . . 18 Plasminogen activator inhibitor type 1 (human, PAI-1). . . . . . . . 20 Pneumolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Poliovirus type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Poliovirus type 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Poliovirus type 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Pregnancy-associated plasma protein A (human, PAPP-A) . . . 18 Procollagen type I C-terminal propeptide (human, PICP) . . . . . 18 Procollagen type IIA N-terminal propeptide (human, PIIANP) . 18 Properdin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Protein C (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Protein S (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

I
IgE (human, non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IgG/k control antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Immunoglobulin heavy chain (chicken, IgY) . . . . . . . . . . . . . . . . . Immunoglobulin light chain (rat, chain) . . . . . . . . . . . . . . . . . . . . Influenza A virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Influenza B virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 21 19 19 19 19

L
LDL, (human, MDA-treated) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Leptin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 L-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Lipocalin-2 (dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Lipocalin-2 (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 7, 18 Lipocalin-2 (monkey) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Lipocalin-2 (mouse) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Lipocalin-2 (pig) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Lipocalin-2 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

R
Rat NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18

S
Streptolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Surfactant protein A (human, hSP-A) . . . . . . . . . . . . . . . . . . . . . . . 13 Surfactant protein D (human, hSP-D) . . . . . . . . . . . . . . . . . . . . . . . 14 Siderocalin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4, 5, 6, 7, 18

M
Mannan-binding lectin (chicken, MBL). . . . . . . . . . . . . . . . . . . . . . 15 Mannan-binding lectin (human, horse, pig, MBL) . . . . . . . . . . . . 15 Mannan-binding lectin (human, MBL) . . . . . . . . . . . . . . . . . . . 10, 15 Mannan-binding lectin (rat, MBL) . . . . . . . . . . . . . . . . . . . . . . . . . . 15 MBL standard serum (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 MBL Oligomer deficient serum (human) . . . . . . . . . . . . . . . . . . . . 21 MDA treated low-density lipoprotein (human, LDL) . . . . . . . . . . 21 M-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 MHC class I chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 MHC class II chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Monkey NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Mouse NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 18 Mycobacterium tuberculosis, Ag85 . . . . . . . . . . . . . . . . . . . . . . . . 19 Mycobacterium tuberculosis, ESAT-6 . . . . . . . . . . . . . . . . . . . . . . 19 Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) . . 19

T
Tetanus toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Tetranectin (human). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Thioguanine (2-amino-6-mercaptopurine) . . . . . . . . . . . . . . . . . . 20 Thrombin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Thrombospondin I (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Tissue plasminogen activator (human, tPA) . . . . . . . . . . . . . . . . . 20 Trypsin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Tumor necrosis factor (human, TNF-). . . . . . . . . . . . . . . . . . . . 17

U
Urokinase plasminogen activator (human, uPA) . . . . . . . . . . . . . 20 Urokinase plasminogen activator receptor (human, uPAR) . . . 20

V
Vasoactive intestinal peptide (human, bovine, porcine, rat, VIP) . . . . . . . . . . . . . . . . . . . . . . . . . . Vitamin-D binding protein (human) . . . . . . . . . . . . . . . . . . . . . . . . . Vitronectin (bovine, horse, rabbit) . . . . . . . . . . . . . . . . . . . . . . . . . . Vitronectin (bovine, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vitronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vitronectin (human, dog, cat, rabbit, bovine) . . . . . . . . . . . . . . . . Vitronectin (human, dog, cat, sheep) . . . . . . . . . . . . . . . . . . . . . . . von Willebrand factor (human, vWf) . . . . . . . . . . . . . . . . . . . . . . . . 17 21 12 12 12 12 12 13

N
Neuropeptide Y (human, rat, mouse, NPY) . . . . . . . . . . . . . . . . . . 17 NGAL (dog, neutrophil gelatinase-associated lipocalin) . . . . 7, 18 NGAL (human, neutrophil gelatinase-associated lipocalin) . 4, 7, 18 NGAL (monkey, neutrophil gelatinase-associated lipocalin) . . . .7, 18 NGAL (mouse, neutrophil gelatinase-associated lipocalin). . . . .7, 18 NGAL (pig, neutrophil gelatinase-associated lipocalin) . . . . . 7, 18 NGAL (rat, neutrophil gelatinase-associated lipocalin) . . . . . 7, 18 Nitrobacter hamburgensis nitrite oxidoreductase . . . . . . . . . . . . 19

23

Ordering

Ordering information
Products should be ordered from your local BioPorto Diagnostics distributor. If there is no distributor in your country, please order directly from BioPorto Diagnostics. BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark VAT number DK-1864 5882 Phone (+45) 4529 0000 Fax (+45) 4529 0001 Mail Web info@bioporto.com www.bioporto.com

Diagnostics

Terms and conditions


Returns
No returns can be accepted without prior written approval by the ordering channel (distributor or BioPorto Diagnostics). Only unopened merchandise that has been handled and stored as prescribed can be returned. No return of custom manufactured products will be authorized if the product meets the specifications agreed upon prior to shipment.

Alternate right Storage

BioPorto Diagnostics reserves the right to change product specifications (e.g. buffer system) to maximize product quality. Directions given on an individual datasheet or label are an integral part of these terms and conditions and must be strictly followed.

Reservation of title

Unless otherwise marked, all products are for research use or further manufacture only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. Product codes: GAU*, MON* and DIA 011-01B, are not for further manufacture either. CE-marked products comply with EU Directive 98/79/EC on in vitro diagnostic medical devices and are for in vitro diagnostic use in countries that recognize this legislation. The NGAL Rapid ELISA Kit (KIT 037) is for in-vitro diagnostic (IVD) use in selected countries. Please visit www.bioporto.com for availability in your country. The MBL Oligomer ELISA Kit (KIT 029) is for in-vitro diagnostic (IVD) use in selected countries. Please visit www.bioporto.com for availability in your country. All products remain the property of BioPorto Diagnostics A/S until full payment has been received. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics be responsible for loss of profits or indirect consequential losses resulting from use of its products.

For more information


24

Contact your local distributor or BioPorto Diagnostics.

Distributors

Distributors
Belgium
ImTec Diagnostics N.V. Hortensiastraat 12 2020 Antwerpen Phone: +32 3 225 1139 Fax: +31 297 56 34 58 E-mail: info@imtec.be Guangdong, Guangxi, Fujian and Hainan provinces Guangzhou Dahui Biotech Co. Ltd. Room 2808, Floor 28, Huihua Commerce and Trade Building No.80 Xianlie Zhong Road Guangzhou, Guangdong Province 510070 Phone: +86 20 3763 6952 +86 20 3763 6935 Fax: +86 20 3763 6953 Web: www.dahuibio.com

Diagnostics

Brazil

Science Pro Rua Rafael Correa Sampaio, 1186 09541-250 So Caetano do Sul - SP Phone: +55 11 4221 6609 Fax: +55 11 4224 1388 E-mail: sciencepro@sciencepro.com.br Web: www.sciencepro.com.br

France

Canada

Socit COGER 79, Rue des Morillons FR-75015 Paris Phone: +33 145 33 67 17 Fax: +33 145 32 71 04 E-mail: info@coger.fr Web: www.coger.fr

AFFINITY Diagnostics Corp. 288 Wildcat Road Toronto, Ontario M3J 2N5 Toll Free: +1 877 370 6300 Phone: +1 416 650 6300 Fax: +1 416 650 5990 E-mail: info@affinitydiagnostics.ca Web: www.affinitydiagnostics.ca Cedarlane Laboratories Ltd. 4410 Paletta Court Burlington, Ontario, L7L 5R2 Toll Free: +1 800 268 5058 Phone: +1 289 288 0001 Fax: +1 289 288 0020 E-mail: general@cedarlanelabs.com Web: www.cedarlanelabs.com/Canada

Germany

dianova GmbH Warburgstrae 45 D-20354 Hamburg Phone: +49 40 45 06 70 Fax: +49 40 45 06 74 90 E-mail: info@dianova.de Web: www.dianova.de

Greece

Czech Republic

Anachem 9 Adrianiou Str. 11525 N. Psihiko, Athens Phone: +30 210 67 41 765 Fax: +30 210 67 41 278 E-mail: info@anachem.gr Web: www.anachem.gr

LAB MARK a.s. Pod Cihelnou 23 161 00 Praha 6 Phone: +420 233 335 548 Fax: +420 233 335 930 E-mail: labmark@labmark.cz Web: www.labmark.cz

India

China

Shanghai, Zhejiang, Jiangsu, Jiangxi, Anhui and Henan provinces Seebio Biotech, Inc. 11-502, No.299 Bi Sheng Road (The First Shanghai Centre) Zhang Jiang Hi-Tech Zone Shanghai 201204 Free call: 800 988 1820 Phone: +86 21 5027 2975 +86 21 5027 2976 Fax: +86 21 5027 2979 E-mail: service@seebio.cn Web: www.cxbio.com Web: www.seebio.cn Beijing, Tianjin, Hebei, Shanxi, Shandong, Heilongjiang, Jilin, Liaoning, Neimenggu, Xinjiang, Qinghai, Gansu, Ningxia, Shanxi and Hong Kong provinces NeoBioscience Technology Company 17C2-2, Unit E, Peng An Building, No.20 Yuanda Road Haidian District, Beijing 100089 Phone: +86 108859 4029 ext 804 Fax: +86 10 8859 4129 ext 808 E-mail: info@neobioscience.com Web: www.neobioscience.com

Tamil Nadu, Andhra Pradesh, Gujarat, Goa, Kerala, Karnataka, Maharashtra, Puducherry, Andamans, Nicobar and Lakshwadeep CPC Diagnostics Pvt. Ltd. No.9, 5th floor, Gokul Tower 9&10 C.P. Ramaswamy Road Alwarpet, Chennai - 600 018 Phone: +91 44 24993989 Fax: +91 44 24993357 E-mail: immuno@cpcdiagnostics.in Web: www.cpcdiagnostics.in Dehli, Punjab, Haryana, U.P., Bihar, Jharkhand, West Bengal, J&K, H. P., Uttarakhand, Assam, A.P., Rajasthan, Madhya Pradesh, Chhattisgarh and Orissa Immunoshop India Pvt. Ltd. 309, Raheja Arcade, Sector-11, CBD, Belapur Navi Mumbai - 400614 Phone: +91 22 27566891 +91 22 27566892 Fax: +91 27 566893 E-mail: info@immunoshop.com Web: www.immunoshop.com

Indonesia

PT. Genetika Science Indonesia (An affiliate of vCell Science Pte.) Jln. Keadilan Raya No. 17F Jakarta Barat 11130 Phone: +62 21 6345687 Fax: +62 21 6345689 E-mail: info@ptgenetika.com Web: www.ptgenetika.com

25

Distributors

Iran

Mahdia Teb Zist Co. Ltd. No.28 Ghanbare Jafari (180E) Tehranpars, Tehran - 1655937311 Phone: +98 21 7729 7231 Mobile: +98 912 383 3420 Fax: +98 21 7787 8790 E-mail: Info@mahdiateb.com

Luxembourg

ImTec Diagnostics N.V. Hortensiastraat 12 2020 Antwerpen, Belgium Phone: +32 3 225 1139 Fax: +31 297 56 34 58 E-mail: info@imtec.be

Ireland
Diagnostics

Malaysia

Caltag-Medsystems Ltd. Botyl Road, Botolph Claydon MK18 2LR Buckingham Free call: 800 279 9113 Phone: +44 (0)1296 715459 Fax: +44 (0)1296 715718 E-mail: sales@caltagmedsystems.co.uk Web: www.caltagmedsystems.co.uk

Axon Scientific Sdn Bhd (An affiliate of vCell Science Pte.) No. 13-4, Jalan SP2/1 Taman Serdang Perdana 43300 Seri Kembangan Selangor DE Phone: +603 89451482 Fax: +603 89419421 E-mail: info@axonscientific.com Web: www.axonscientific.com

Israel

Almog Diagnostic and Medical Equipment Ltd. P.O. Box 349 Shoham 60850 Phone: +972 3 9773390 Fax: +972 3 9773391 E-mail: info@almog.co.il Web: www.almog.co.il

Netherlands

ITK diagnostics BV Joh. Enschedeweg 13 NL-1422 DR Uithoorn Phone: +31 297 56 88 93 Fax: +31 297 56 34 58 E-mail: info@itk.nl Web: www.itk.nl

Italy

Bio Exe SRL Via Albere 132 IT-37137 Verona Phone: +39 045 8904496 Fax: +39 045 8625313 E-mail: info@bioexe.it Web: www.bioexe.it

Pakistan

Japan

Friends Scientific Corporation 3-B Ali Continental 1-Mozang Road Lahore-54000 Phone: +92 42 7236176 +92 42 7350926 Fax: +92 42 7321500 E-mail: friends1@wol.net.pk

Funakoshi Co., Ltd. 9-7 Hongo, 2-chome, Bunkyo-ku 113-003 Tokyo Phone: +81 3 5684 1620 Fax: +81 3 5684 1775 E-mail: info@funakoshi.co.jp Web: www.funakoshi.co.jp

Poland

Dong-In Biotech Co., Ltd. 19-9 Geoyeodong Songpaku, Seoul 138-110 Phone: +82 2 2043 7375 Fax: +82 2 431 0645
E-mail: Web: info@donginbiotech.co.kr www.donginbiotech.co.kr

Korea

DRG MedTek Sp. zo.o ul. Wita Stwosza 24 02-661 Warszawa Phone: +48 22 847 82 44 +48 22 847 83 75 Fax: +48 22 843 72 74 E-mail: office@drgmedtek.pl Web: www.drgmedtek.pl DRG MedTek South Poland ul. Piotra Skargi 28 44-100 Gliwice E-mail: drg_wj@medianet.pl Web: www.drg.alpha.pl

KOMA Biotech Inc. 301, Gayang Technotown, #1487 Gayang 3 dong, Gangseo-gu Seoul 157-793 Phone: +82 2 579 8787 Fax: +82 2 578 7042
E-mail: Web: koma@komabiotech.co.kr www.komabiotec.co.kr

Portugal

bioactiva diagnostica Louisen Str. 11 D-61348 Bad Homburg - Germany Phone: +49 6172 17102 0 Fax: +49 6172 17102 29 E-mail: bioactiva@bioactiva.de Web: www.bioactiva.de

Kuwait

INODIA Inovao Diagnstica e Mdica, Lda. Rua General Silva, n41 A 2 Esq 1800-208 Lisbon Phone: +351 919994372 Fax: +351 211808178 E-mail: rita.ferreira@inodia.pt Web: www.inodia.pt

Romania

Canori imex SRL 9-15 Maior Coravu Str. Bl. C5, Sc. B, Ap. 51, Sector 2 Bucharest Phone: +40 21 250 19 29 Fax: +40 21 250 19 06 E-mail: office@canori.ro Web: www.canori.ro

26

Distributors

Singapore

vCell Science Pte Ltd. 41 Science Park Road, The Gemini Singapore Science Park II, Singapore 117610 Phone: +65 6778 8166 Fax: +65 6778 8132 E-mail: info@vcellscience.com Web: www.vcellscience.com

United Kingdom

Slovakia

Caltag-Medsystems Ltd Botyl Road, Botolph Claydon MK18 2LR Buckingham Free call: 800 279 9113 Phone: +44 (0)1296 715459 Fax: +44 (0)1296 715718 E-mail: sales@caltagmedsystems.co.uk Web: www.caltagmedsystems.co.uk

LAB MARK a.s. Pod Cihelnou 23 161 00 Praha 6 Phone: +420 233 335 548 Fax: +420 233 335 930 E-mail: labmark@labmark.cz Web: www.labmark.cz

USA

Diagnostics

South Africa

ABR Affinity BioReagents (Thermo Fisher Scientific) 4620 Technology Drive Suite 600, Golden, CO 80403 Free call: 800 527 4535 Phone: +1 303 278 4535 Fax: +1 303 278 2424 E-mail: affinity@bioreagents.com Web: www.bioreagents.com Assay Designs, Inc 5777 Hines Drive Ann Arbor, MI 48108 Free call: 800 833 8651 Phone: +1 734 668 6113 Fax: +1 734 668 2793 E-mail: info@assaydesigns.com Web: www.assaydesigns.com Cedarlane Laboratories U.S.A. 1210 Turrentine Street Burlington, NC 27215 Free call: 800 721 1644 Phone: +1 336 513 5135 Fax: +1 336 513 5138 E-mail: service@cedarlanelabs.com Web: www.cedarlanelabs.com/us Quidel Corporation Specialty Products Group 2981 Copper Road, Santa Clara, CA 95051 Free call: 800 524 6318 Phone: +1 408 616 4301 Fax: +1 408 616 4310 E-mail: custsvc.spg@quidel.com Web: www.quidel.com

Biocom Biotech P.O. Box 13004 0014 Clubview Phone: +27 12 654 4614 Fax: +27 86 654 9048 E-mail: info@biocombiotech.co.za Web: www.biocombiotech.co.za

Spain

LabClinics S.A. C. Industria, 54 E-08025 Barcelona Phone: +34 93 446 47 00 Fax: +34 93 348 10 39 E-mail: info@labclinics.com Web: www.labclinics.com

Sri Lanka

CPC Diagnostics Pvt. Ltd. No.9, 5th floor, Gokul Tower 9&10 C.P. Ramaswamy Road Alwarpet, Chennai - 600 018 Phone: +91 44 24993989 Fax: +91 44 24993357 E-mail: immuno@cpcdiagnostics.in Web: www.cpcdiagnostics.in

Lucerna Chem AG Abendweg 18 CH-6006 Luzern Phone: +41 41 420 96 36 Fax: +41 41 420 96 56 E-mail: lucerna-chem@lucerna-chem.ch Web: www.lucerna-chem.ch

Switzerland

Taiwan

Blossom Biotechnologies Inc. 2F-6, No.32, Sec. 1, Cheng-gung Rd. Nangang 11570, Taipei Phone: +886 2 2788 2121 Fax: +886 2 2782 9911 E-mail: blossom@blossombio.com.tw Web: www.blossombio.com.tw

Turkey

MedSanTek Ltd. Co. Millet Cad. Findikzade Sok. Emre Apt. No:19/5 34093, Findikzade-Istanbul Phone: +90 212 635 85 46 Fax: +90 212 635 83 50 E-mail: info@medsantek.com.tr Web: www.medsantek.com

27

Distributed by:

Diagnostics
BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark Phone Fax E-mail Web (+45) 4529 0000 (+45) 4529 0001 info@bioporto.com www.bioporto.com
70004/102009/e

Você também pode gostar